BioSpace News Archive

Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001.

Codexis, Inc. announced it has entered into a purchase agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science, for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency.

Eli Lilly and Company announced the successful completion of its acquisition of POINT Biopharma Global Inc., a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.

Vistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system disorders, announced that the European Patent Office issued a Notice of Intention to Grant a patent related to the use of AV-101 for the treatment of neuropathic pain.

SELLAS Life Sciences Group, Inc. announced follow-up clinical/immune-response data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S, combined with the checkpoint inhibitor nivolumab in patients with refractory/relapsed malignant pleural mesothelioma.

RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. announced the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therapeutics in an all-stock transaction.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the appointment of Gunnar Olsson as CEO has been extended.

TLC BioSciences announced that the company will present at the 42nd Annual JP Morgan Healthcare Conference at 2:00pm PT on Tuesday, January 9, 2024.

Synlogic, Inc. announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab prime contract to develop a manufacturing process to support development of a potential live probiotic product.